サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1792741

分子ファーミングの世界市場

Molecular Pharming

出版日
ページ情報
英文 495 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
分子ファーミングの世界市場
出版日: 2025年08月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 495 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

分子ファーミングの世界市場は2030年までに23億米ドルに到達

2024年に17億米ドルと推定される分子ファーミングの世界市場は、2024年から2030年にかけてCAGR 5.9%で成長し、2030年には23億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるトウモロコシ作物は、CAGR5.0％を記録し、分析期間終了時には6億740万米ドルに達すると予想されます。大麦作物セグメントの成長率は、分析期間中CAGR 4.6％と推定されます。

米国市場は4億4,980万米ドルと推定される一方、中国はCAGR 9.1％で成長すると予測される

米国の分子ファーミング市場は、2024年には4億4,980万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億6,830万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と5.7％と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界の分子ファーミング市場- 主要動向と促進要因まとめ

分子ファーミングとは何か？

分子ファーミングとは、ワクチン、抗体、酵素、治療用タンパク質などの医薬品物質を生産するために、遺伝子組み換え植物を使用することを指します。この技術は植物バイオテクノロジーと医薬品製造を組み合わせたもので、植物を複雑な生物製剤のバイオファクトリーとして機能させる。分子ファーミングは、従来の細胞ベースや微生物生産システムに代わる、スケーラブルで低コスト、かつ汚染に強い生産システムを提供する可能性があるとして注目を集めています。

タバコ、トウモロコシ、イネ、さらにはレタスなどの作物を用いることで、研究者は治療用タンパク質をコードする特定の遺伝子を発現させることができます。これらのタンパク質は、医療用に採取・精製されます。分子ファーミングは、大量に生物製剤を生産するのに特に適しており、特に低資源環境や、迅速かつ費用対効果の高い製造が重要である保健緊急時の生産に適しています。その重要性は、従来の生産インフラの制限を回避しながら、生物製剤に対する世界の需要の高まりに対応する能力にあります。

この分野の技術とプロセスはどのように進歩しているのか？

遺伝子工学、植物形質転換技術、タンパク質発現システムの進歩は、分子ファーミングの効率と実行可能性を著しく向上させています。アグロバクテリウムを介した遺伝子導入、ウイルスベクターを用いた一過性発現、CRISPRに基づく遺伝子編集などの技術は、収量の最適化と開発期間の短縮に役立っています。精製プロセスも進化しており、新しい手法によって、構造や機能を損なうことなく高純度のタンパク質を回収できるようになりました。

現在では、モノクローナル抗体、インスリンアナログ、酵素補充療法を植物組織内で直接発現させることができるようになりました。一貫性を維持し、医薬品グレードの基準を満たすために、水耕栽培された植物を封じ込めた環境で使用するアプローチもあります。規制の枠組みは、商業的なスケールアップをサポートするために徐々に適応してきており、いくつかの植物由来の生物製剤はすでに使用が承認されています。このような開発により、特にニッチあるいは大量生産の治療ニーズに対して、植物由来の生産システムに対する信頼が高まっています。

分子ファーミングはどこで応用され、誰が主要利害関係者か？

分子ファーミングは、ワクチン開発、感染症治療、がん治療、希少遺伝子疾患など、いくつかの分野で応用されています。主な成功例の一つは、エボラウイルスや狂犬病ウイルスに対する抗体の生産です。研究機関、バイオテクノロジー企業、製薬会社は、生物学的製剤のパイプラインを多様化し、進化する世界ヘルスの優先課題に対応するため、植物由来のプラットフォームに投資しています。

学術研究センターは初期段階の開発と概念実証研究で中心的な役割を果たし、民間企業はスケールアップ、製剤化、薬事承認に重点を置いています。開発途上地域の政府や保健機関は、分子ファーミングを必要不可欠な医薬品の生産においてより大きな自立を達成するための手段と見なしています。公的機関とバイオテクノロジー企業のパートナーシップは、特に従来のモデルでは商業的インセンティブに欠ける疾病のワクチンや治療法の生産において、一般的になりつつあります。

分子ファーミング市場の成長を促進する要因は何か？

分子ファーミング市場の成長は、生物製剤に対する需要の高まり、従来の製造システムの限界、柔軟でスケーラブルな製造プラットフォームの必要性など、いくつかの要因によってもたらされます。分子ファーミングは、インフラや原材料の面でコスト優位性があり、発展途上国で安価な治療薬を生産する上で魅力的です。新興感染症に対応した生産を迅速に展開できることも、関心を高める重要な利点です。

植物バイオテクノロジーの進歩、合成生物学への投資の増加、下流の精製技術の進歩は、収量や一貫性に関する過去の制限を克服するのに役立っています。規制機関や公衆衛生機関からの支援の高まりも、より幅広い採用を後押ししています。世界のヘルスケア・システムが弾力性のある分散型製造ソリューションを求める中、分子ファーミングは、より迅速かつ持続可能な方法で将来の治療ニーズに応えるための実行可能なアプローチとして台頭してきています。

セグメント

作物ソース（トウモロコシ作物、大麦作物、タバコ作物、サフラワー作物、イネ作物、アルファルファ作物）、技術（遺伝子銃技術、農業浸透技術、エレクトロポレーション技術、アグロバクテリウム媒介遺伝子導入技術、その他の技術）、用途（組換え抗体用途、ホルモン用途、ワクチン用途、工業用酵素用途、タンパク質・タンパク質系材料用途、技術試薬用途、その他用途）、最終用途（バイオ・製薬企業最終用途、CRO最終用途、その他最終用途）

調査対象企業の例

  • Agrenvec S.L.
  • Avaxin Biologics
  • Baiya Phytopharm
  • BioBetter Ltd.
  • Bright Biotech
  • Cape Bio Pharms（Cape Biologix Tech.）
  • Diamante S.r.l.
  • Elo Life Systems
  • Leaf Expression Systems
  • Medicago Inc.
  • Miruku
  • Moolec Science SA
  • MOZZA（Mozza Foods）
  • Nobell Foods
  • ORF Genetics hf.
  • PlantForm Corporation
  • Planet Biotechnology Inc.
  • ProdiGene Inc.
  • Protalix Biotherapeutics, Inc.
  • Tiamat Sciences Corp.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37427

Global Molecular Pharming Market to Reach US$2.3 Billion by 2030

The global market for Molecular Pharming estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Maize Crop, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$607.4 Million by the end of the analysis period. Growth in the Barley Crop segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$449.8 Million While China is Forecast to Grow at 9.1% CAGR

The Molecular Pharming market in the U.S. is estimated at US$449.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$468.3 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Molecular Pharming Market - Key Trends & Drivers Summarized

What Is Molecular Pharming and Why Is It Gaining Momentum?

Molecular pharming refers to the use of genetically modified plants to produce pharmaceutical substances such as vaccines, antibodies, enzymes, and therapeutic proteins. This technique combines plant biotechnology with pharmaceutical manufacturing, allowing plants to function as biofactories for complex biologics. Molecular pharming is gaining attention for its potential to offer scalable, low-cost, and contamination-resistant alternatives to traditional cell-based or microbial production systems.

By using crops such as tobacco, maize, rice, and even lettuce, researchers can express specific genes that encode therapeutic proteins. These proteins are then harvested and purified for medical use. Molecular pharming is particularly suited for producing biologics in large volumes, especially in low-resource settings or during health emergencies where rapid and cost-effective manufacturing is critical. Its growing relevance lies in its ability to meet rising global demand for biologics while bypassing the limitations of conventional production infrastructure.

How Are Technologies and Processes Advancing in This Field?

Advancements in genetic engineering, plant transformation techniques, and protein expression systems have significantly improved the efficiency and viability of molecular pharming. Technologies such as Agrobacterium-mediated gene transfer, transient expression using viral vectors, and CRISPR-based gene editing are helping optimize yields and reduce development time. Purification processes have also evolved, with new methods enabling the recovery of high-purity proteins without damaging their structure or function.

Innovations now allow expression of monoclonal antibodies, insulin analogs, and enzyme replacement therapies directly within plant tissues. Some approaches use hydroponically grown plants in contained environments to maintain consistency and meet pharmaceutical-grade standards. Regulatory frameworks are gradually adapting to support commercial scale-up, with a few plant-derived biologics already approved for use. These developments are expanding confidence in plant-based production systems, especially for niche or high-volume therapeutic needs.

Where Is Molecular Pharming Being Applied and Who Are the Key Stakeholders?

Molecular pharming is being applied in several areas including vaccine development, infectious disease treatment, cancer therapy, and rare genetic disorders. One of its major successes has been the production of antibodies against Ebola and rabies viruses. Research institutions, biotech firms, and pharmaceutical companies are investing in plant-based platforms to diversify their biologics pipelines and respond to evolving global health priorities.

Academic research centers play a central role in early-stage development and proof-of-concept studies, while private-sector players focus on scale-up, formulation, and regulatory approval. Governments and health organizations in developing regions view molecular pharming as a means to achieve greater self-reliance in essential medicine production. Partnerships between public institutions and biotech companies are becoming more common, especially for producing vaccines and treatments for diseases that lack commercial incentives under traditional models.

What Factors Are Driving Growth In The Molecular Pharming Market?

Growth in the molecular pharming market is driven by several factors including rising demand for biologics, limitations of traditional manufacturing systems, and the need for flexible, scalable production platforms. Molecular pharming offers cost advantages in terms of infrastructure and raw materials, making it attractive for producing affordable therapies in developing countries. The ability to rapidly deploy production in response to emerging infectious diseases is another key benefit driving interest.

Advances in plant biotechnology, increased investment in synthetic biology, and progress in downstream purification technologies are helping overcome past limitations related to yield and consistency. Growing support from regulatory bodies and public health institutions is also encouraging wider adoption. As global healthcare systems look for resilient and decentralized manufacturing solutions, molecular pharming is emerging as a viable approach to meeting future therapeutic needs with greater speed and sustainability.

SCOPE OF STUDY:

The report analyzes the Molecular Pharming market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Crop Source (Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop, Alfalfa Crop); Technology (Gene Gun Technology, Agro infiltration Technology, Electroporation Technology, Agrobacterium-Mediated Gene Transfer Technology, Other Technologies); Application (Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application, Other Applications); End-Use (Biotech & Pharma Companies End-Use, CROs End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Agrenvec S.L.
  • Avaxin Biologics
  • Baiya Phytopharm
  • BioBetter Ltd.
  • Bright Biotech
  • Cape Bio Pharms (Cape Biologix Tech.)
  • Diamante S.r.l.
  • Elo Life Systems
  • Leaf Expression Systems
  • Medicago Inc.
  • Miruku
  • Moolec Science SA
  • MOZZA (Mozza Foods)
  • Nobell Foods
  • ORF Genetics hf.
  • PlantForm Corporation
  • Planet Biotechnology Inc.
  • ProdiGene Inc.
  • Protalix Biotherapeutics, Inc.
  • Tiamat Sciences Corp.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Molecular Pharming - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Cost-Effective Biopharmaceuticals Propels Adoption of Molecular Pharming Technologies
    • Rising Interest in Plant-Based Protein Expression Systems Strengthens Business Case for Alternative Drug Production
    • Expansion of Therapeutic Protein and Vaccine Development Drives Innovation in Molecular Pharming Platforms
    • Reduced Risk of Human Pathogen Contamination in Plant Systems Accelerates Regulatory Acceptance
    • Technological Advancements in Gene Editing and Plant Transformation Enhance Efficiency and Product Yield
    • Growth in Monoclonal Antibody Research Fuels Demand for Scalable Plant-Based Expression Systems
    • Increasing Pressure to Lower Biologic Drug Production Costs Spurs Investment in Molecular Pharming Startups
    • Global Vaccine Access Initiatives Highlight Potential of Plant-Derived Vaccines for Rapid, Scalable Deployment
    • Expansion of Biodefense and Pandemic Preparedness Programs Throws Spotlight on Fast-Track Production Methods
    • Growing Need for Cold Chain-Free Biologics Enhances Suitability of Plant-Based Pharmaceutical Products
    • Increased Application of Molecular Pharming in Veterinary Biologics Broadens End-Use Market Scope
    • Demand for Plant-Derived Enzymes and Industrial Proteins Drives Cross-Sector Adoption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Molecular Pharming Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Molecular Pharming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Molecular Pharming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Molecular Pharming by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Maize Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Maize Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Maize Crop by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Barley Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Barley Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Barley Crop by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Tobacco Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Tobacco Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Tobacco Crop by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Safflower Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Safflower Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Safflower Crop by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Rice Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Rice Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Rice Crop by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Alfalfa Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Alfalfa Crop by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Alfalfa Crop by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Agrobacterium-Mediated Gene Transfer Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Agrobacterium-Mediated Gene Transfer Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Agrobacterium-Mediated Gene Transfer Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Gene Gun Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Gene Gun Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Gene Gun Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Agro infiltration Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Agro infiltration Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Agro infiltration Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Electroporation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Electroporation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Electroporation Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Recombinant Antibodies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Recombinant Antibodies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Recombinant Antibodies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Hormones Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Hormones Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Hormones Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Industrial Enzymes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Industrial Enzymes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Industrial Enzymes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Proteins & Protein-based Materials Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Proteins & Protein-based Materials Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Proteins & Protein-based Materials Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Technical Reagents Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Technical Reagents Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: World 16-Year Perspective for Technical Reagents Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 59: World Recent Past, Current & Future Analysis for Biotech & Pharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: World Historic Review for Biotech & Pharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: World 16-Year Perspective for Biotech & Pharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 62: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 63: World Historic Review for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: World 16-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 65: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 68: USA Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: USA 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 71: USA Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: USA Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: USA 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 74: USA Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: USA Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: USA 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 77: USA Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: USA Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: USA 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Canada 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Canada 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Canada Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Canada 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 89: Canada Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Canada Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Canada 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Japan 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Japan 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Japan Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Japan 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 101: Japan Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Japan Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Japan 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 104: China Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: China 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: China 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: China 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 113: China Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: China Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: China 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Molecular Pharming by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Molecular Pharming by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Europe 16-Year Perspective for Molecular Pharming by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Europe 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Europe 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Europe 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 128: Europe Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Europe Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Europe 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 131: France Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: France 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: France 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: France 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 140: France Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: France Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: France 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Germany 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Germany 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Germany 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 152: Germany Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Germany Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Germany 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Italy 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Italy 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Italy 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 164: Italy Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Italy Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Italy 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 167: UK Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: UK 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 170: UK Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: UK Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: UK 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 173: UK Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: UK 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 176: UK Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: UK Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: UK 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Spain 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 182: Spain Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Spain Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Spain 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 185: Spain Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Spain Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Spain 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 188: Spain Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Spain Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Spain 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Russia 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 194: Russia Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Russia Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Russia 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 197: Russia Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Russia Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Russia 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 200: Russia Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Russia Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Russia 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Europe Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Europe 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Europe Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Europe 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 212: Rest of Europe Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Europe Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Rest of Europe 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Molecular Pharming by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 16-Year Perspective for Molecular Pharming by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Asia-Pacific Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Asia-Pacific 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Asia-Pacific Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Asia-Pacific 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 227: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Asia-Pacific Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Asia-Pacific 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Australia 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 233: Australia Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Australia Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Australia 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 236: Australia Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Australia Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Australia 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 239: Australia Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Australia Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Australia 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 242: India Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: India 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 245: India Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: India Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: India 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 248: India Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: India Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: India 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 251: India Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: India Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: India 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: South Korea 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 257: South Korea Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: South Korea Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: South Korea 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 260: South Korea Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: South Korea Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: South Korea 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 263: South Korea Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: South Korea Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: South Korea 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Rest of Asia-Pacific Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Rest of Asia-Pacific 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Rest of Asia-Pacific Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Rest of Asia-Pacific 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 275: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Rest of Asia-Pacific Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Rest of Asia-Pacific 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Molecular Pharming by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Molecular Pharming by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Latin America 16-Year Perspective for Molecular Pharming by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Latin America 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 284: Latin America Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Latin America Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Latin America 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 287: Latin America Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Latin America Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Latin America 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 290: Latin America Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Latin America Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Latin America 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Argentina 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 296: Argentina Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Argentina Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Argentina 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 299: Argentina Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Argentina Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Argentina 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 302: Argentina Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Argentina Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Argentina 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Brazil 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 308: Brazil Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Brazil Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Brazil 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 311: Brazil Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Brazil Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Brazil 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 314: Brazil Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Brazil Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Brazil 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 319: Mexico 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 320: Mexico Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Mexico Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 322: Mexico 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 323: Mexico Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Mexico Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 325: Mexico 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 326: Mexico Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Mexico Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 328: Mexico 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Rest of Latin America Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 334: Rest of Latin America 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Rest of Latin America Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 337: Rest of Latin America 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 338: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Rest of Latin America Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 340: Rest of Latin America 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Molecular Pharming by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Molecular Pharming by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 343: Middle East 16-Year Perspective for Molecular Pharming by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 346: Middle East 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 347: Middle East Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Middle East Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 349: Middle East 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 350: Middle East Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Middle East Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 352: Middle East 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 353: Middle East Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Middle East Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 355: Middle East 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 358: Iran 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 359: Iran Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Iran Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 361: Iran 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 362: Iran Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Iran Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 364: Iran 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 365: Iran Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Iran Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 367: Iran 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 370: Israel 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 371: Israel Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Israel Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 373: Israel 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 374: Israel Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Israel Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 376: Israel 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 377: Israel Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Israel Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 379: Israel 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Saudi Arabia Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 385: Saudi Arabia 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Saudi Arabia Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 388: Saudi Arabia 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 389: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Saudi Arabia Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 391: Saudi Arabia 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 394: UAE 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 395: UAE Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: UAE Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 397: UAE 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 398: UAE Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: UAE Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 400: UAE 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 401: UAE Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: UAE Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 403: UAE 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Rest of Middle East Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 409: Rest of Middle East 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Rest of Middle East Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 412: Rest of Middle East 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 413: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Rest of Middle East Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 415: Rest of Middle East 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Molecular Pharming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Molecular Pharming by Crop Source - Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 418: Africa 16-Year Perspective for Molecular Pharming by Crop Source - Percentage Breakdown of Value Sales for Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop and Alfalfa Crop for the Years 2014, 2025 & 2030
    • TABLE 419: Africa Recent Past, Current & Future Analysis for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Africa Historic Review for Molecular Pharming by Technology - Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 421: Africa 16-Year Perspective for Molecular Pharming by Technology - Percentage Breakdown of Value Sales for Agrobacterium-Mediated Gene Transfer Technology, Other Technologies, Gene Gun Technology, Agro infiltration Technology and Electroporation Technology for the Years 2014, 2025 & 2030
    • TABLE 422: Africa Recent Past, Current & Future Analysis for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Africa Historic Review for Molecular Pharming by Application - Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 424: Africa 16-Year Perspective for Molecular Pharming by Application - Percentage Breakdown of Value Sales for Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 425: Africa Recent Past, Current & Future Analysis for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Africa Historic Review for Molecular Pharming by End-Use - Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 427: Africa 16-Year Perspective for Molecular Pharming by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, CROs End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION